January 05, 2021
Las Vegas, NV - Southern Hills Hospital and Medical Center is seeing success with a new treatment called bamlanivimab to treat COVID19 patients. The monoclonal antibody treatment is in the same family of medication as the treatment President Trump received when he was stricken with covid-19.
Bamlanivimab was authorized in November by the FDA for use in COVID-19 patients with mild to moderate disease who were at high risk of progressing to severe disease.
“While we have seen promising results in reducing hospitalizations for those who received the treatment, we want to stress there is no better way to combat COVID19 than with the vaccine,” said Dr. Domenic Martinello, Chief Medical Officer at Southern Hills Hospital.
Bamlanivimab should be given as soon as possible after a positive COVID test result and within 10 days of COVID-19 symptom onset. The antibody treatment is given once via a 60 minute transfusion.
Since November, Southern Hills Hospital has administered more than 120 doses of bamlanivimab.
Patients must meet the following criteria to receive bamlanivimab:
Patients With ≥1 of the Following:
- BMI ≥35
- Chronic kidney disease
- Immunosuppressive disease
- Currently receiving immunosuppressive treatment
- ≥65 years old
Patients ≥55 Years Old and ≥1 of the Following:
- Cardiovascular disease
- COPD or other chronic respiratory disease
Patients 12-17 Years Old and ≥1 of the Following:
- BMI ≥85th percentile for their age and gender
- Sickle cell disease
- Congenital or acquired heart disease
- Neurodevelopmental disorders (eg, cerebral palsy)
- A medical-related technological dependence (eg, tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])
- Asthma, reactive airway or other chronic respiratory disease that requires daily treatment